



GlaxoSmithKline

INTERMEDIARY

QUALITY STATEMENT

Priorix™ Vaccine

AMJRB606AI

The Priorix vaccine lot AMJRB606AI has been produced in compliance with the Good Manufacturing Practices and meets the requirements of our specifications.

These lots have been checked by GSK Biologicals Quality Assurance and Quality Control according to our procedures.

No deviation that could be linked to the complaint has been highlighted.

Batches reviewed:

AMJRB606AI

Filling: AMJRB606A

Formulation: AMJRB606

Bulk: ARUBAVA006, ARUBAHA006, AMUJAVA090, AMUJAVA112,

AMUJAVA113, AMESAVA030, AMESAHA030

The retained samples of the final container conform to the specification.

No incident during distribution and no cold chain deviation that can be linked to the adverse event were recorded.

No other adverse event or technical complaint was reported for this batch.

The Quality statement will be updated upon completion of the batch review.

This lot has also been controlled, tested and released by the *Belgian National Control Authority (ISP)*.

February 03, 2010

Virginie Graide

GlaxoSmithKline Biologicals

Global Quality Assurance Specialist

GQA- Distribution Management

A handwritten signature in black ink, appearing to read 'Graide', is written over a horizontal line. The signature is enclosed within a large, hand-drawn oval shape.